Summary by Moomoo AI
On February 12, 2024, the United States Securities and Exchange Commission (SEC) addressed a letter to Amro Albanna, CEO of Aditxt, Inc., regarding the company's amended registration statement filed on January 26, 2024. The SEC's correspondence includes comments on the amendment No. 1 to Aditxt's Registration Statement on Form S-1, specifically requesting additional information and clarification. The SEC has asked Aditxt to consider including pro forma financial statements and financial statements of Evofem Biosciences, Inc., in line with specific regulatory guidance, following Aditxt's merger agreement with Evofem announced on December 11, 2023. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. Furthermore, the SEC inquired about the need for pro forma information and financial statements related to the acquisition...Show More
